Fullhope Biomedical Co EBITDA TCAC 5A

Que fait Fullhope Biomedical Co ? Fullhope Biomedical Co Ltd is a Taiwan-based biotechnology company headquartered in Taipei. The company operates in the health care sector with a focus on precision diagnosis and regenerative medicine. Fullhope Biomedical went public on September 26, 2024, with its ticker listed as 7773.TWO. The company's website is https://www.fhb.com.tw/. In the precision diagnosis sector, Fullhope Biomedical has developed an immune function analysis platform and a circulating tumor cell analysis platform. These platforms provide comprehensive information on immune system status and circulating tumor cell data, which can inform follow-up disease treatment strategies. For regenerative medicine, the company maintains a Good Tissue Practice (GTP) laboratory that adheres to regulatory standards. It has established a full-scale manufacturing platform for immune cells and stem cells, producing various cell-based products. The company's operations are based in Taipei, Taiwan, and it is engaged in developing and commercializing products related to precision diagnostics and regenerative medicine. Fullhope Biomedical's business model centers on leveraging advanced biotechnological platforms to support medical treatments and patient care. The company's IPO date marks its entry into the public market, reflecting its growth and development in the biotechnology industry. Fullhope Biomedical's focus on innovative diagnostic and therapeutic solutions positions it within the expanding health care technology sector. Fullhope Biomedical Co est l'une des entreprises les plus populaires sur Eulerpool.